1-trifluoromethyl-1-cyclobutylcarboxylic acid is a useful trifluoromethylated cyclobutane building block for synthesis of various pharmaceutical compounds, e.g. bombesin receptor, subtype-3 modulators, Flaviviridae viruses inhibitors, GPR119 agonists and SGLT2 inhibitors, etc..
Selective reactions of 1,1-cycloalkanedicarboxylic acids with SF4. a route to 1,1-bis(trifluoromethyl)cycloalkanes, 1-fluoroformyl-1-(trifluoromethyl) cycloalkanes and 1-(trifluoromethyl)-1-cycloalkanecarboxylic acids. 
Solid-phase synthesis of aryl, heteroaryl, and sterically hindered alkyl amines using the Curtius rearrangement. 
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1, 1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. 
Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection. 
Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome. 
Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain. 
 W.Dmowski, et al, J. F. Chem., 2002, 102(1-2), pp 141-146.
 S.Sunami, et al, Tetrahedron, 2009, 65(3), pp 638-643.
 M.W.Rowbottom, et al, J. Med. Chem., 2012, 55(3), pp 1082-1105.
 S.E.Lazerwith, et al, J. Med. Chem. 2014, 57(5), pp 1893-1901.
 Y.Ren, et al, J. Med. Chem., 2017, 60(3), pp 972-986.